E. Swann

发表

Recruitment of Caribbean female commercial sex workers at high risk of HIV infection.

J. Pape, Karine Sévère, M. Deschamps, 2013, Revista panamericana de salud publica = Pan American journal of public health.

Conceptual framework for behavioral and social science in HIV vaccine clinical research.

H. Meissner, Zuhayr Kafaar, J. Stansbury, 2011, Vaccine.

Does per‐act HIV‐1 transmission risk through anal sex vary by gender? An updated systematic review and meta‐analysis

A. van der Straten, R. Baggaley, M. Boily, 2018, American journal of reproductive immunology.

Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP® DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults

J. Kublin, N. Sardesai, D. Weiner, 2020, Vaccines.

Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

M. Wulfsohn, S. Hammer, R. Schooley, 2012, PLoS medicine.

First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).

Jennifer A. Johnson, J. Goudsmit, D. Barouch, 2013, The Journal of infectious diseases.

Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.

S. Hammer, H. Liao, T. Hertz, 2016, The Journal of infectious diseases.

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)

Galit Alter, David C Montefiori, Nigel Garrett, 2018, The Lancet.

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

H. Schuitemaker, M. Robb, P. Goepfert, 2022, The New England journal of medicine.

Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.

N. Frahm, E. Karita, M. McElrath, 2016, Annals of internal medicine.

Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans.

Jennifer A. Johnson, D. Milner, D. Barouch, 2015, The Journal of infectious diseases.

Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand.

Jerome H. Kim, S. Peel, L. Jagodzinski, 2016, The New England journal of medicine.

First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002).

Jennifer A. Johnson, D. Barouch, M. Seaman, 2014, The Journal of infectious diseases.

Helios expressing regulatory T cells are correlated with decreased IL-2 producing CD8 T cells and antibody diversity in Mozambican individuals living chronically with HIV-1

M. Robb, I. Jani, L. Kestens, 2021, BMC immunology.

Feasibility of Identifying a Female Sex Worker Cohort at High Risk of HIV Infection in the Caribbean for HIV Vaccine Efficacy Trials: Longitudinal Results of HVTN 907

M. Deschamps, Y. Donastorg, C. Morgan, 2016, Journal of acquired immune deficiency syndromes.

Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.

H. Liao, B. Haynes, J. Fuchs, 2015, Journal of AIDS & clinical research.

Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk.

Allan C. deCamp, S. Hammer, J. Mascola, 2019, The Journal of clinical investigation.

Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa

J. Kublin, D. Montefiori, M. McElrath, 2019, Science Translational Medicine.

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial

Lindsay N. Carpp, Vicki C. Ashley, Allan C. deCamp, 2022 .

Transient Peripheral Immune Activation follows Elective Sigmoidoscopy or Circumcision in a Cohort Study of MSM at Risk of HIV Infection

S. Buchbinder, M. McElrath, S. D. De Rosa, 2016, PloS one.

Advancing long-acting and extended delivery HIV prevention and treatment regimens through behavioral science: NIH workshop directions.

T. Senn, M. Stirratt, W. Chege, 2021, AIDS.

Feasibility of Identifying a Cohort of US Women at High Risk for HIV Infection for HIV Vaccine Efficacy Trials: Longitudinal Results of HVTN 906

D. Dunbar, I. Frank, B. Koblin, 2013, Journal of acquired immune deficiency syndromes.

Recruitment of Urban US Women at Risk for HIV Infection and Willingness to Participate in Future HIV Vaccine Trials

D. Dunbar, D. Metzger, I. Frank, 2013, AIDS and Behavior.

How common and frequent is heterosexual anal intercourse among South Africans? A systematic review and meta-analysis

A. van der Straten, R. Baggaley, M. Boily, 2017, Journal of the International AIDS Society.

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial

D. Montefiori, G. Pantaleo, M. McElrath, 2019, The Journal of clinical investigation.

Robust antibody and cellular responses induced by DNA-only vaccination for HIV.

N. Sardesai, D. Weiner, Jian Yan, 2020, JCI insight.

Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features

Lindsay N. Carpp, Mathieu Le Gars, Ilse C. L. Van Dromme, 2023, Research square.

HIV Sexual Risk and Syndemics among Women in Three Urban Areas in the United States: Analysis from HVTN 906

V. Frye, D. Dunbar, I. Frank, 2015, Journal of Urban Health.

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial

Lindsay N. Carpp, Vicki C. Ashley, Allan C. deCamp, 2018, The Journal of infectious diseases.

Risk of COVID-19 after natural infection or vaccination

Nicole L. Nollen, Eric A. Meyerowitz, Waseem M. Chughtai, 2023, EBioMedicine.